Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CYT997

Known as: Tubulin Inhibitor CYT997 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

LexibulinPyridinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma
BackgroundOsteosarcoma (OS) is a common malignant cancer in children and adolescents and has a cure rate that has not improved in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CYT997 through enhancing excessively high reactive oxygen species-induced apoptosis
The functional relationship between apoptosis and autophagy in anticancer drug treatment is extremely complex, and the molecular… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity
BackgroundAbnormalities of tubulin polymerization and microtubule assembly are often seen in cancer, which make them very… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins
The orally active microtubule-depolymerizing agent CYT997 is potently cytotoxic to a variety of tumors in vitro and in vivo… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
The Microtubule Depolymerizing Agent CYT997 Causes Extensive Ablation of Tumor Vasculature In Vivo
The orally active microtubule-disrupting agent (S)-1-ethyl-3-(2-methoxy-4-(5-methyl-4-((1-(pyridin-3-yl)butyl)amino)pyrimidin-2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2010
2010
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
Background:CYT997 is a novel microtubule inhibitor and vascular-disrupting agent with marked preclinical anti-tumour activity… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
2009
2009
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
CYT997 is a wholly synthetic compound that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
Discovery of CYT997: a structurally novel orally active microtubule targeting agent.
CYT997 was discovered as a potent tubulin polymerization inhibitor possessing potent cytotoxic activity against a range of cancer… Expand
2009
2009
CYT997 Causes apoptosis in human multiple myeloma
SummaryMultiple Myeloma (MM) is an incurable malignancy of mature plasma cells. Microtubule targeting agents (MTAs) are an… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2009
2009
Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer.
3568 Background: CYT997 is a novel, small-molecule vascular disrupting agent which binds tubulin and inhibits microtubule… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE